Vertex Pharmaceuticals Incorporated

Equities

VRTX

US92532F1003

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 24/05/2024 BST 5-day change 1st Jan Change
457 USD +1.36% Intraday chart for Vertex Pharmaceuticals Incorporated +2.64% +12.30%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Vertex Pharmaceuticals Insider Sold Shares Worth $3,168,704, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $6,795,294, According to a Recent SEC Filing MT
ADDvise Group’s Axelerist Bags $1.4 Million Order for Medical, Lab Equipment MT
Vertex Pharmaceuticals Incorporated completed the acquisition of Alpine Immune Sciences, Inc. from a group of shareholders. CI
Vertex Pharmaceuticals Incorporated Appoints Jennifer Schneider as Independent Director CI
Wolfe Research Adjusts Price Target on Vertex Pharmaceuticals to $520 From $497 MT
Alpine Immune Sciences, Vertex Pharmaceuticals Deal Crosses Another Milestone MT
FOMO is Back Our Logo
ANALYST RECOMMENDATIONS : Nvidia, The Home Depot, Lowe's, Rollins... Our Logo
Leerink Partners Adjusts Vertex Pharmaceuticals' Price Target to $529 From $511 MT
Stifel Adjusts Vertex Pharmaceuticals' Price Target to $420 From $430 MT
Piper Sandler Adjusts Price Target on Vertex Pharmaceuticals to $456 From $450, Keeps Overweight Rating MT
Morgan Stanley Adjusts Price Target on Vertex Pharmaceuticals to $402 From $413, Keeps Equalweight Rating MT
RBC Adjusts Price Target on Vertex Pharmaceuticals to $424 From $417, Keeps Sector Perform Rating MT
Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $577 From $574, Keeps Buy Rating MT
Bernstein Adjusts Price Target on Vertex Pharmaceuticals to $458 From $450, Keeps Market Perform Rating MT
Vertex Pharmaceuticals Q1 Non-GAAP EPS, Revenue Increase MT
Vertex Pharmaceuticals 1Q Sales Up 13% on Cystic Fibrosis Drug DJ
Transcript : Vertex Pharmaceuticals Incorporated, Q1 2024 Earnings Call, May 06, 2024
Earnings Flash (VRTX) VERTEX PHARMACEUTICALS INCORPORATED Reports Q1 EPS $4.76, vs. Street Est of $4.06 MT
Vertex Pharmaceuticals Reiterates FY 2024 Total Product Revenue Guidance of $10.55-$10.75 Billion MT
Vertex Pharmaceuticals Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Vertex tops Q1 profit estimates on robust demand for cystic fibrosis treatments RE
Vertex Pharmaceuticals Incorporated Re-Iterates Earnings Guidance for the Full Year 2024 CI
Equity Markets Higher as Traders Parse Fed Official's Remarks MT
Chart Vertex Pharmaceuticals Incorporated
More charts
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
457 USD
Average target price
462.8 USD
Spread / Average Target
+1.28%
Consensus
  1. Stock Market
  2. Equities
  3. VRTX Stock
  4. News Vertex Pharmaceuticals Incorporated
  5. Vertex Pharmaceuticals Says FDA Granted Rolling Review of Suzetrigine to Treat Acute Pain